Nasdaq:CERT
Certara, Inc.
Certara (CERT) delivers high-value computational modeling software to accelerate drug and device development in the life sciences sector.
Key Metrics
Investment Thesis
Bull Case
Certara represents an attractive turnaround opportunity given its dominant market share in niche PBPK modeling where few competitors exist. The company's strong positive operating cash flow of $96.3M provides financial flexibility to invest in R&D and return capital to shareholders through buybacks. As the life sciences sector continues to prioritize cost-efficient drug development, demand for Certara's proprietary simulation tools is expected to grow organically.
Bear Case
The company's recurring net losses of $1.6M raise concerns about long-term profitability despite growing revenue trends from $335.6M in 2022 to $418.8M in 2025. High levels of goodwill at $773.3M and significant amortization charges of $73.0M create substantial non-cash burdens that suppress reported earnings quality. Investors should worry about the sustainability of current margins if competition intensifies or if key clients reduce spending on optional simulation services.
About Certara, Inc.
Certara, Inc. (CERT) is a global leader in computational modeling software serving life sciences and healthcare markets. The company provides simulation tools that help pharmaceutical and medical device manufacturers optimize clinical trial designs and reduce development costs. Its primary revenue streams include subscription licensing for advanced modeling platforms, professional services, and data analytics solutions.
Analysis
Management Discussion
Despite generating $418.8M in revenue for 2025, the company reported a net loss of $1.6M, indicating persistent challenges in covering high operating expenses and amortization costs. Cash flow from operations improved to $96.3M, providing necessary liquidity to fund R&D and share repurchases totaling $42.6M while maintaining a healthy cash balance of $189.4M. The reduction in net loss compared to the previous year suggests improving operational efficiency, though the continued deficit highlights the capital-intensive nature of maintaining advanced computational modeling infrastructure.
Industry Overview
The life sciences software industry is experiencing rapid growth driven by the need for digital transformation in clinical research and regulatory compliance. Companies are increasingly adopting computational modeling to reduce the time and cost associated with bringing new drugs to market, creating a favorable environment for specialized vendors. However, consolidation among large tech providers poses a threat to independent software firms that must continuously innovate to maintain their niche positions.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $335.6M | $354.3M | $385.1M | $418.8M |
| Cost of Revenue | $132.6M | $141.0M | $154.5M | $161.1M |
| Gross Profit | $203.1M | $213.3M | $230.6M | $257.7M |
| Operating Expenses | $170.5M | $254.1M | $232.4M | $236.7M |
| Operating Income | $32.5M | $-40.8M | $-1.7M | $21.0M |
| R&D | $28.2M | $34.2M | $37.1M | $41.0M |
| G&A | $71.8M | $95.4M | $94.2M | $85.4M |
| Marketing | $27.4M | $32.0M | $47.4M | $53.7M |
| Stock-Based Comp | $30.3M | $28.3M | $34.8M | $33.1M |
| D&A | $1.7M | $1.6M | $2.0M | $75.2M |
| Depreciation | — | — | — | $2.2M |
| Amortization | $50.7M | $54.5M | $66.0M | $73.0M |
| Other OpEx | $43.2M | $92.5M | $53.6M | $56.6M |
| Non-Operating Income | $-13.8M | $-14.4M | $-15.5M | $-13.4M |
| Interest Expense | $17.8M | $22.9M | — | — |
| Pre-Tax Income | $18.8M | $-55.1M | $-17.2M | $7.6M |
| Income Tax | $4.0M | $214.0K | $-5.1M | $9.2M |
| Continuing Ops | $14.7M | $-55.4M | $-12.1M | $-1.6M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $14.7M | $-55.4M | $-12.1M | $-1.6M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $14.7M | $-55.4M | $-12.1M | $-1.6M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $342.3M | $340.2M | $310.9M | $315.1M |
| Cash & Equivalents | $236.6M | $235.0M | $179.2M | $189.4M |
| Accounts Receivable | $72.2M | $75.4M | $90.6M | $94.6M |
| Prepaid Expenses | $20.0M | $20.4M | $29.5M | $22.2M |
| Other Current Assets | $13.4M | $9.4M | $11.6M | $9.0M |
| Long-Term Assets | $1.23B | $1.22B | $1.26B | $1.24B |
| PP&E (Net) | $2.4M | $2.7M | $2.2M | $1.9M |
| Goodwill | $717.7M | $716.3M | $757.0M | $773.3M |
| Operating Leases | $14.4M | $9.6M | $13.8M | $11.9M |
| Other LT Assets | $496.1M | $494.3M | $491.2M | $454.4M |
| Total Assets | $1.57B | $1.56B | $1.58B | $1.56B |
| Current Liabilities | $103.2M | $130.0M | $146.1M | $153.4M |
| Accounts Payable | $7.5M | $5.2M | $3.5M | $3.4M |
| Current Debt | $3.0M | $3.0M | $3.0M | $3.0M |
| Current Leases | $5.0M | $4.4M | $5.3M | $3.9M |
| Taxes Payable | $2.2M | $1.0M | $430.0K | $1.4M |
| Other Current Liab | $50.0M | $59.7M | $77.4M | $74.5M |
| Long-Term Liabilities | $390.1M | $386.3M | $370.4M | $340.4M |
| Long-Term Debt | $290.0M | $288.2M | $292.4M | $290.1M |
| LT Operating Leases | $10.1M | $7.0M | $11.2M | $8.4M |
| Other LT Liab | $90.0M | $91.1M | $66.8M | $41.8M |
| Total Liabilities | $493.3M | $516.3M | $516.4M | $493.8M |
| Shareholders' Equity | $1.08B | $1.05B | $1.06B | $1.06B |
| Paid-In Capital | $1.15B | $1.18B | $1.22B | $1.26B |
| Retained Earnings | $-60.9M | $-116.2M | $-128.3M | $-129.9M |
| AOCI | $-8.2M | $-7.6M | $-13.4M | $2.0M |
| Total L&E | $1.57B | $1.56B | $1.58B | $1.56B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $14.7M | $-55.4M | $-12.1M | $-1.6M |
| Non-Cash Adjustments | $44.3M | $144.6M | $64.3M | $96.1M |
| Working Capital Changes | $33.5M | $-6.4M | $28.2M | $1.9M |
| Cash from Operations | $92.5M | $82.8M | $80.5M | $96.3M |
| Capital Expenditures | $1.4M | $1.8M | $1.6M | $1.8M |
| Cash from Investing | $-27.8M | $-79.5M | $-112.4M | $-26.6M |
| Debt Issuances | — | $0 | — | — |
| Share Buybacks | — | — | — | $42.6M |
| Cash from Financing | $-7.4M | $-9.4M | $-21.0M | $-64.0M |
| FX Effect | $-4.3M | $1.5M | $-2.9M | $4.4M |
| Net Change in Cash | $53.1M | $-4.7M | $-55.8M | $10.2M |
| Beginning Cash | $186.6M | $239.7M | $235.0M | $179.2M |
| Ending Cash | $239.7M | $235.0M | $179.2M | $189.4M |
Frequently Asked Questions
How does Certara, Inc. make money?
The company operates primarily through its Simcyp division which focuses on physiologically-based pharmacokinetic (PBPK) modeling for small molecules, alongside its PK-Sim platform for large molecules. Revenue is further diversified into professional services that support clinical trial design, regulatory submissions, and biotechnology consulting. Additionally, the firm generates income from data licensing and cloud-based analytics services that integrate with major electronic health record systems.
What are the main risks for CERT?
Regulatory changes in the US and EU could alter reimbursement models or approval pathways, directly impacting demand for clinical trial optimization software. The company faces intense competition from large technology giants like Oracle and Microsoft who are increasingly entering the specialized life sciences software market with bundled solutions. Heavy reliance on a concentrated customer base in the pharmaceutical sector exposes CERT to significant revenue volatility if major clients delay projects or cut spending during economic downturns.
What is CERT's competitive advantage?
Certara holds a dominant market position due to its extensive proprietary databases containing decades of human tissue and protein binding data that competitors cannot easily replicate. The company benefits from high switching costs as pharmaceutical clients rely on deep integration of CERT's simulation tools within their existing regulatory submission workflows. Its strong intellectual property portfolio in computational biology creates significant barriers to entry for new software entrants.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.